Why the study?
Does short hairpin RNA targeting the 2B gene of coxsackievirus B3 reduce viral replication and improve survival in CVB3-infected mice and cells?
Does short hairpin RNA targeting the 2B gene of coxsackievirus B3 reduce viral replication and improve survival in CVB3-infected mice and cells?
Lentivirus-delivered shRNA targeting the 2B gene of coxsackievirus B3 significantly reduces viral replication and improves survival in a murine model of viral myocarditis.
shRNA-2B merits further preclinical testing in viral myocarditis; leaves open clinical translation from this murine model.
BACKGROUND: Coxsackievirus B3 is an important infectious agent of viral myocarditis, pancreatitis and aseptic meningitis, but there are no specific antiviral therapeutic reagents in clinical use. RNA interference-based technology has been developed to prevent the viral infection. METHODS: To evaluate the impact of RNA interference on viral replication, cytopathogenicity and animal survival, short hairpin RNAs targeting the viral 2B region (shRNA-2B) expressed by a recombinant vector (pGCL-2B) or a recombinant lentivirus (Lenti-2B) were tansfected in HeLa cells or transduced in mice infected with CVB3. RESULTS: ShRNA-2B exhibited a significant effect on inhibition of viral production in HeLa cells. Furthermore, shRNA-2B improved mouse survival rate, reduced the viral tissues titers and attenuated tissue damage compared with those of the shRNA-NC treated control group. Lenti-2B displayed more effective role in inhibition of viral replication than pGCL-2B in vivo. CONCLUSIONS: Coxsackievirus B3 2B is an effective target of gene silencing against coxsackievirus B3 infection, suggesting that shRNA-2B is a potential agent for further development into a treatment for enterviral diseases.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: